Senti Bio Receives RMAT Designation and Presents New AML Data at ASH Annual Meeting

Senti Biosciences participated in a virtual investor CEO Connect segment to discuss its groundbreaking AML data at the American Society of Hematology Annual Meeting and recently granted RMAT designation for SENTI-202, a potential first-in-class cell therapy for relapsed/refractory hematologic malignancies, including AML. The RMAT designation builds on the Orphan Drug Designation granted in June.